ONCBeiGeneFinished
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 53 (final count)
- Started
- Apr 25, 2022
- Main results expected
- Aug 30, 2024
- Fully finished
- Aug 30, 2024
- Results posted
- Sep 15, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: From first dose of study drug up to 30 days after last dose, maximum time on treatment was 98 weeks.
Recommended Phase 2 Dose (RP2D) of Ociperlimab When Administered in Combination With Tislelizumab or Rituximab
Measured over: 21 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05267054 · record last updated 2025-09-15 · checked 2026-11-09 15:47 UTC